Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways-Case Report and Literature Review

被引:7
|
作者
Jurca, Claudia Maria [1 ,2 ]
Kozma, Kinga [1 ,2 ]
Petchesi, Codruta Diana [1 ,2 ]
Zaha, Dana Carmen [1 ]
Magyar, Ioan [1 ]
Munteanu, Mihai [3 ]
Faur, Lucian [3 ]
Jurca, Aurora [4 ]
Bembea, Dan [5 ]
Severin, Emilia [6 ]
Jurca, Alexandru Daniel [1 ]
机构
[1] Univ Oradea, Fac Med & Pharm, Dept Preclin Disciplines, Oradea 410081, Romania
[2] Cty Emergency Clin Hosp Oradea, Reg Ctr Med Genet Bihor, Oradea 410469, Romania
[3] Univ Oradea, Fac Med & Pharm, Dept Med Disciplines, Oradea 410081, Romania
[4] Univ Oradea, Fac Med & Pharm, Oradea 410081, Romania
[5] Univ Med & Pharm Iuliu Hatieganu, Fac Med, Cluj Napoca 400012, Romania
[6] Univ Med & Pharm Carol Davila, Dept Genet, Bucharest 020021, Romania
关键词
tuberous sclerosis; hamartomas; TSC1; TSC2; epilepsy; type 2 diabetes mellitus; Metformin; MAMMALIAN TARGET; GLUCOSE-UPTAKE; COMPLEX; TSC1; MTOR; CELL; KINASE; EXPRESSION; MANAGEMENT; METFORMIN;
D O I
10.3390/genes14020433
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Tuberous sclerosis complex (TSC) is a rare autosomal dominant neurocutaneous syndrome. It is manifested mainly in cutaneous lesions, epilepsy and the emergence of hamartomas in several tissues and organs. The disease sets in due to mutations in two tumor suppressor genes: TSC1 and TSC2. The authors present the case of a 33-year-old female patient registered with the Bihor County Regional Center of Medical Genetics (RCMG) since 2021 with a TSC diagnosis. She was diagnosed with epilepsy at eight months old. At 18 years old she was diagnosed with tuberous sclerosis and was referred to the neurology department. Since 2013 she has been registered with the department for diabetes and nutritional diseases with a type 2 diabetes mellitus (T2DM) diagnosis. The clinical examination revealed: growth delay, obesity, facial angiofibromas, sebaceous adenomas, depigmented macules, papillomatous tumorlets in the thorax (bilateral) and neck, periungual fibroma in both lower limbs, frequent convulsive seizures; on a biological level, high glycemia and glycated hemoglobin levels. Brain MRI displayed a distinctive TS aspect with five bilateral hamartomatous subependymal nodules associating cortical/subcortical tubers with the frontal, temporal and occipital distribution. Molecular diagnosis showed a pathogenic variant in the TSC1 gene, exon 13, c.1270A>T (p. Arg424*). Current treatment targets diabetes (Metformin, Gliclazide and the GLP-1 analog semaglutide) and epilepsy (Carbamazepine and Clonazepam). This case report presents a rare association between type 2 diabetes mellitus and Tuberous Sclerosis Complex. We suggest that the diabetes medication Metformin may have positive effects on both the progression of the tumor associated with TSC and the seizures specific to TSC and we assume that the association of TSC and T2DM in the presented cases is accidental, as there are no similar cases reported in the literature.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review
    Sun, K.
    Luo, J.
    Guo, J.
    Yao, X.
    Jing, X.
    Guo, F.
    OSTEOARTHRITIS AND CARTILAGE, 2020, 28 (04) : 400 - 409
  • [2] The Roles of PI3K/AKT/mTOR and MAPK/ERK Signaling Pathways in Human Pheochromocytomas
    Du, Juan
    Tong, Anli
    Wang, Fen
    Cui, Yunying
    Li, Chunyan
    Zhang, Yushi
    Yan, Zhaoli
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2016, 2016
  • [3] PI3K/mTOR Signaling Pathways in Medulloblastoma
    Mohan, Avinash L.
    Friedman, Marissa D.
    Ormond, D. Ryan
    Tobias, Michael
    Murali, Raj
    Jhanwar-Uniyal, Meena
    ANTICANCER RESEARCH, 2012, 32 (08) : 3141 - 3146
  • [4] Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer
    Morgos, Diana-Theodora
    Stefani, Constantin
    Miricescu, Daniela
    Greabu, Maria
    Stanciu, Silviu
    Nica, Silvia
    Stanescu-Spinu, Iulia-Ioana
    Balan, Daniela Gabriela
    Balcangiu-Stroescu, Andra-Elena
    Coculescu, Elena-Claudia
    Georgescu, Dragos-Eugen
    Nica, Remus Iulian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
  • [5] Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
    Dimitrova, V.
    Arcaro, A.
    CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 82 - 93
  • [6] Targeting PI3K/Akt/mTOR signaling in cancer
    Porta, Camillo
    Paglino, Chiara
    Mosca, Alessandra
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [7] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [8] A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway
    Fu, Jiahui
    Liang, Peili
    Zheng, Yingchun
    Xu, Cailing
    Xiong, Fu
    Yang, Fang
    GENE, 2024, 909
  • [9] The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
    Tian, Ling-Yu
    Smit, Daniel J.
    Juecker, Manfred
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [10] Metformin induces apoptosis of melanoma B16 cells via PI3K/Akt/mTOR signaling pathways
    Tian, Ye
    Zhao, Lili
    JOURNAL OF BUON, 2020, 25 (04): : 2066 - 2070